eClinical Tech News

Propanc Biopharma has signed a services agreement with Berlin-based FyoniBio to develop and validate an LC-MS pharmacokinetics assay capable...

Aptorum Group and DiamiR Biosciences reported peer‑reviewed evidence that plasma microRNA signatures can detect glioblastoma, publishing feasibility findings in...

In earlier clinical work, the alpibectir–ethionamide combination (AlpE) delivered a 7‑day early bactericidal activity signal comparable to isoniazid and...

BridgeBio’s BBP-418 delivered functional and biomarker gains in the Phase 3 FORTIFY interim analysis for LGMD2I/R9: at 12 months,...

In updated interim data from the Phase 1/2 INSPIRE DUCHENNE study, 40 participants have received SGT-003 to date. Among...

Patients adherent to the monthly extended-release buprenorphine injection for 12 months posted 42% lower adjusted non-MOUD medical costs compared...

At 14 months post-transplant, a single patient in an investigator-sponsored study maintained detectable fasting and meal-stimulated C-peptide, with mixed-meal...

SELLAS’ CDK9 inhibitor SLS009 (tambiciclib) previously delivered a 33% overall response rate across evaluable relapsed/refractory AML patients, rising to...

Aplagon has dosed the first patient in HEALING, a Phase 2a study of APAC in chronic limb-threatening ischemia secondary...

Cbio has received regulatory clearance to initiate a first‑in‑human Phase I/IIa study of novoleucel in persistent or recurrent cervical...